Sanofi
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SNYN.MX | PFE | GLAXO.BO | SANOFI.BO | NVS | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | 2.03T | 175.50B | 423.63B | 77.83B | 311.59B | 37.61B |
| P/E (TTM) | 23.9 | 44.0 | 44.4 | 21.4 | 31.5 | 110.2 |
| Forward P/E | — | 10.6 | 36.9 | 19.0 | 16.6 | 15.6 |
| Price/book | 1.3 | 2.1 | 24.8 | 9.4 | 8.4 | 2.0 |
| Dividend yield | 4.94% | 5.59% | 1.75% | 3.56% | 2.87% | — |
| 1-year change | −7.28% | +23.90% | +6.17% | −27.27% | +30.35% | +62.35% |
| Today | 0.00% | +2.63% | −1.26% | +0.11% | +3.59% | +2.22% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All SNYN.MX news ›Nurix says Sanofi discontinues autoimmune disease drug program
Nov 3 (Reuters) – Nurix Therapeutics said on Tuesday that Sanofi has decided to discontinue development of an experimental treatment for autoimmune and inflammatory diseases, eliminating potential future milestone payments and royalties…
AstraZeneca targets $1.5B in savings; Ayrmid bids for Karyopharm; Sanofi pays $125M to Novavax
AstraZeneca is cutting costs and early cancer programs, while Ayrmid is pursuing another struggling U.S. drugmaker. This week’s six updates also include a Huntington’s gene therapy review, mixed MS data and new plans for vaccines and…
Nurix Shares Drop 35% After Sanofi Scraps Oral Immunology Drug
Nurix Therapeutics, Inc. (NRIX) lost roughly a third of its market value in extended trading Tuesday after Sanofi said it is walking away from an experimental oral drug licensed from the clinical-stage biotech. The Paris-based…
Cutaneous Lupus Erythematosus Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and ROA Trends | Biogen, Horizon Therapeutics, Bristol-Myers Squibb, AstraZeneca, Sanofi, Amgen
Albany New York November 03 2026 As per DelveInsight s assessment globally Cutaneous Lupus Erythematosus pipeline constitutes 8 key companies continuously working towards developing 10 Cutaneous Lupus Erythematosus treatment therapies…
Sanofi SA News — BMV:SAN1/N
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the…
Sanofi 2026 Q3 - Results - Earnings Call Presentation
2026-11-03. The following slide deck was published by Sanofi in conjunction with their 2026 Q3 earnings call. The following slide deck was published by Sanofi in conjunction with their 2026 Q3 earnings call.
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30,…
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
Sanofi is pursuing deals for late-stage and commercial medicines after delivering another beat-and-raise quarter that emphasized its reliance on Dupixent. “We are laser-focused on ensuring growth beyond Dupixent [loss of exclusivity],”…
Sanofi raises full-year outlook again
Faglig rådgiver til ATMP Danmark Head of Clinical Operations Clinical Trial Program Lead Senior Specialist, Drug Product Head of Medical Affairs International Markets Global Regulatory Strategy Lead, Senior Director Senior Scientist /…
Sanofi (SNY) Q3 2026 Earnings Call Transcript
Dupixent sales surge 34.8% as Sanofi upgrades full-year guidance on portfolio momentum. Friday, Oct. 30, 2026 Either raise your hand in Zoom or submit your question using the Q&A feature. Now I hand you over to Belén. Overall, the…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com29
- seekingalpha.com15
- markets.businessinsider.com6
- finance.biggo.com3
- ir.recursion.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.